383 related articles for article (PubMed ID: 22953645)
1. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
Agrillo A; Nastro Siniscalchi E; Facchini A; Filiaci F; Ungari C
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
Bozas G; Roy A; Ramasamy V; Maraveyas A
Onkologie; 2010; 33(6):321-3. PubMed ID: 20523097
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.
Hoefert S; Eufinger H
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):463-9. PubMed ID: 20692189
[TBL] [Abstract][Full Text] [Related]
4. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
McKay RR; Lin X; Perkins JJ; Heng DY; Simantov R; Choueiri TK
Eur Urol; 2014 Sep; 66(3):502-9. PubMed ID: 24613250
[TBL] [Abstract][Full Text] [Related]
7. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Beuselinck B; Wolter P; Karadimou A; Elaidi R; Dumez H; Rogiers A; Van Cann T; Willems L; Body JJ; Berkers J; Van Poppel H; Lerut E; Debruyne P; Paridaens R; Schöffski P
Br J Cancer; 2012 Nov; 107(10):1665-71. PubMed ID: 23132391
[TBL] [Abstract][Full Text] [Related]
8. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
9. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L
J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843
[No Abstract] [Full Text] [Related]
10. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
Ramírez L; López-Pintor RM; Casañas E; Arriba Ld; Hernández G
Oral Health Prev Dent; 2015; 13(5):385-93. PubMed ID: 25884045
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
Fusco V; Porta C; Saia G; Paglino C; Bettini G; Scoletta M; Bonacina R; Vescovi P; Merigo E; Lo Re G; Guglielmini P; Di Fede O; Campisi G; Bedogni A
Clin Genitourin Cancer; 2015 Aug; 13(4):287-294. PubMed ID: 25586958
[TBL] [Abstract][Full Text] [Related]
12. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
13. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.
Brunello A; Saia G; Bedogni A; Scaglione D; Basso U
Bone; 2009 Jan; 44(1):173-5. PubMed ID: 18849018
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
[TBL] [Abstract][Full Text] [Related]
15. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
16. [Bisphosphonate-associated osteonecrosis of the jaws in lung cancer patients].
Neves I; Morais A; Magalhães A
Rev Port Pneumol; 2013; 19(5):228-32. PubMed ID: 23830508
[TBL] [Abstract][Full Text] [Related]
17. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
[TBL] [Abstract][Full Text] [Related]
18. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the maxillary sinus in bisphosphonate-related osteonecrosis of the jaw: Radiologic aspects.
Wasserzug O; Kaffe I; Lazarovici TS; Weissman T; Yahalom R; Fliss DM; Yarom N
Am J Rhinol Allergy; 2017 Jan; 31(1):36-39. PubMed ID: 28234151
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
Haidar A; Jønler M; Folkmar TB; Lund L
Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
